Latest News and Press Releases

SYDNEY, AUSTRALIA, April 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), advises that it has received a written notification from The Nasdaq Stock...

Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader...

SYDNEY, AUSTRALIA, April 22, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune...

SYDNEY, AUSTRALIA, April 15, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company targeting cancer and autoimmune...

Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM;...

The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's targeted enrolment Futility analysis and completion of...

Media Release Entered into strategic collaboration with Dr. Reddy’s for commercialisation of eftilagimod alfa (efti) in all countries outside North America, Europe, Japan, and Greater ChinaIn January...

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive effect against a strong foreign antigen observed with continued favourable...

The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial’s targeted enrolmentStrong operational progress continues globally with over 120 activated clinical...